Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Alzheimer’s disease

Abdelmaksoud, Nourhan M.; Sallam, Al-Aliaa M.; Abulsoud, Ahmed I.; El-Dakroury, Walaa A.; Abdel Mageed, Sherif S.; AL-Noshokaty, Tohada M.; Elrebehy, Mahmoud A.; Elshaer, Shereen Saeid; Mahmoud, Naira Ali; Fathi, Doaa; Rizk, Nehal I.; Elballal, Mohammed S.; Mohammed, Osama A.; Abdel-Reheim, Mustafa Ahmed; Zaki, Mohamed Bakr; Saber, Sameh; Doghish, Ahmed S.

doi:10.1016/j.prp.2023.155007

Cited by 7 publications

(4 citation statements)

References 304 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This alteration has a notable effect on the development of various neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) [36]. In AD, miRNAs in serum, cerebrospinal fluid, and brain tissue, as well as in transgenic models, have been studied [37][38][39][40][41]. Few studies have reported miRNAs in the early stages or related to the progression of AD [22,[41][42][43][44][45][46].…”

Section: Discussionmentioning

confidence: 99%

“…In AD, miRNAs in serum, cerebrospinal fluid, and brain tissue, as well as in transgenic models, have been studied [37][38][39][40][41]. Few studies have reported miRNAs in the early stages or related to the progression of AD [22,[41][42][43][44][45][46]. Nevertheless, the specific alterations in the transcriptome of mesenchymal stem cells (MSCs) obtained from individuals with familial Alzheimer's disease (FAD) are not yet understood at various stages of the condition.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Rochín-Hernández,

Padilla-Cristerna

et al. 2024

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the predominant form of dementia globally. No reliable diagnostic, predictive techniques, or curative interventions are available. MicroRNAs (miRNAs) are vital to controlling gene expression, making them valuable biomarkers for diagnosis and prognosis. This study examines the transcriptome of olfactory ecto-mesenchymal stem cells (MSCs) derived from individuals with the PSEN1(A431E) mutation (Jalisco mutation). The aim is to determine whether this mutation affects the transcriptome and expression profile of miRNAs and their target genes at different stages of asymptomatic, presymptomatic, and symptomatic conditions. Expression microarrays compare the MSCs from mutation carriers with those from healthy donors. The results indicate a distinct variation in the expression of miRNAs and mRNAs among different symptomatologic groups and between individuals with the mutation. Using bioinformatics tools allows us to identify target genes for miRNAs, which in turn affect various biological processes and pathways. These include the cell cycle, senescence, transcription, and pathways involved in regulating the pluripotency of stem cells. These processes are closely linked to inter- and intracellular communication, vital for cellular functioning. These findings can enhance our comprehension and monitoring of the disease’s physiological processes, identify new disorder indicators, and develop innovative treatments and diagnostic tools for preventing or treating AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Rochín-Hernández,

Padilla-Cristerna

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…A fundamental neurodegenerative process linked to aging in individuals with Alzheimer’s, dementia, Huntington’s, and Parkinson’s disease patients is cognitive loss. Noncoding miRNAs have a major role in CNS, which has led to the discovery of promising novel clinical prospects for these illnesses, which lack current effective therapies ( Abdelmaksoud et al, 2024 ).…”

Section: Mirnas and Age-related Diseasesmentioning

confidence: 99%

Decoding the secrets of longevity: unraveling nutraceutical and miRNA-Mediated aging pathways and therapeutic strategies

Salama,

Eissa,

Doghish

et al. 2024

Front. Aging

Self Cite

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short RNA molecules that are not involved in coding for proteins. They have a significant function in regulating gene expression after the process of transcription. Their participation in several biological processes has rendered them appealing subjects for investigating age-related disorders. Increasing data indicates that miRNAs can be influenced by dietary variables, such as macronutrients, micronutrients, trace minerals, and nutraceuticals. This review examines the influence of dietary factors and nutraceuticals on the regulation of miRNA in relation to the process of aging. We examine the present comprehension of miRNA disruption in age-related illnesses and emphasize the possibility of dietary manipulation as a means of prevention or treatment. Consolidating animal and human research is essential to validate the significance of dietary miRNA control in living organisms, despite the abundance of information already provided by several studies. This review elucidates the complex interaction among miRNAs, nutrition, and aging, offering valuable insights into promising areas for further research and potential therapies for age-related disorders.

show abstract

“…Growing evidence suggests that microRNAs (miRNAs), which are a class of noncoding RNAs that regulates gene expression at the post-transcriptional level, can be potential biomarkers for AD. − Moreover, it has been shown that excreted circulating miRNAs can cross the blood–brain barrier, indicating its potential as biomarkers for neurodegenerative diseases. Additionally, miRNAs have been implicated in neuronal apoptosis regulation and attenuation of Aβ neurotoxicity , and it has been reported that plasma miRNAs are altered prior to the occurrence of symptoms .…”

Section: Introductionmentioning

confidence: 99%

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease

Wen,

Wittens,

Engelborghs

et al. 2024

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common cause of dementia. New strategies for the early detection of MCI and sporadic AD are crucial for developing effective treatment options. Current techniques used for diagnosis of AD are invasive and/or expensive, so they are not suitable for population screening. Cerebrospinal fluid (CSF) biomarkers such as amyloid β1−42 (Aβ1−42), total tau (T-tau), and phosphorylated tau181 (P-tau181) levels are core biomarkers for early diagnosis of AD. Several studies have proposed the use of blood-circulating microRNAs (miRNAs) as potential novel early biomarkers for AD. We therefore applied a novel approach to identify bloodcirculating miRNAs associated with CSF biomarkers and explored the potential of these miRNAs as biomarkers of AD. In total, 112 subjects consisting of 28 dementia due to AD cases, 63 MCI due to AD cases, and 21 cognitively healthy controls were included. We identified seven Aβ1−42-associated plasma miRNAs, six P-tau181associated plasma miRNAs, and nine Aβ1−42-associated serum miRNAs. These miRNAs were involved in AD-relevant biological processes, such as PI3K/AKT signaling. Based on this signaling pathway, we constructed an miRNA-gene target network, wherein miR-145-5p has been identified as a hub. Furthermore, we showed that miR-145-5p performs best in the prediction of both AD and MCI. Moreover, miR-145-5p also improved the prediction performance of the mini-mental state examination (MMSE) score. The performance of this miRNA was validated using different datasets including an RT-qPCR dataset from plasma samples of 23 MCI cases and 30 age-matched controls. These findings indicate that blood-circulating miRNAs that are associated with CSF biomarkers levels and specifically plasma miR-145-5p alone or combined with the MMSE score can potentially be used as noninvasive biomarkers for AD or MCI screening in the general population, although studies in other AD cohorts are necessary for further validation.

show abstract

Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Alzheimer’s disease

Cited by 7 publications

References 304 publications

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Decoding the secrets of longevity: unraveling nutraceutical and miRNA-Mediated aging pathways and therapeutic strategies

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease

Contact Info

Product

Resources

About